Addition of Metastasis-Directed Therapy to Systemic Therapy for Oligometastatic Pancreatic Ductal Adenocarcinoma (EXTEND): A Multicenter, Randomized Phase II Trial.
Ethan Bernard LudmirAlexander D SherryBryan M FellmanSuyu LiuTharakeswara K BathalaCara L HaymakerMarina Nayeli Medina-RosalesAlexandre ReubenEmma B HollidayGrace L SmithSonal S NoticewalaSarah NicholasTracy R PriceRachael M Martin-PaulpeterLuis A PerlesSunyoung S LeeMichael S LeeBrandon G SmagloRyan W HueyJason WillisDan ZhaoLorenzo G CohenCullen M TaniguchiEugene Jon KoayMatthew H G KatzRobert A WolffPrajnan DasShubham PantAlbert C KoongChad TangPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
This study supports the addition of MDT to systemic therapy for patients with oligometastatic PDAC. Induction of systemic immunity is a possible mechanism of benefit. These results warrant confirmatory trials to refine treatment strategy and provide external validation.